反応式
[C:1]([O:5][C:6]([NH:8][C:9]1([C:15]([OH:17])=O)[CH2:14][CH2:13][CH2:12][CH2:11][CH2:10]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].[NH2:18][CH:19]1[CH2:25][CH2:24][C:23]2[CH:26]=[CH:27][CH:28]=[CH:29][C:22]=2[NH:21][C:20]1=[O:30]>>[C:1]([O:5][C:6]([NH:8][C:9]1([C:15]([NH:18][CH:19]2[CH2:25][CH2:24][C:23]3[CH:26]=[CH:27][CH:28]=[CH:29][C:22]=3[NH:21][C:20]2=[O:30])=[O:17])[CH2:10][CH2:11][CH2:12][CH2:13][CH2:14]1)=[O:7])([CH3:2])([CH3:3])[CH3:4]参加物
3
実験手順
Prepared from 1(t-butoxycarbonylamino)cyclohexanecarboxylic acid and 3-amino-2,3,4,5-tetrahydro-1H-[1]benzazepin-2-one (Example 1, Step A) by the procedure described in Example 25, Step A. 1H NMR (200 MHz, CDCl3): 1.1-2.2 (m,19 H), 2.00 (m,2 H), 2.50 (m,2 H), 4.55 (m,1 H), 6.9-7.2 (m,4 H). FAB-MS: calculated for C22H31N3O4 401; found 402 (M+H,40%).
出典と根拠
- ORDレコード
- ord-4cf5c1f8d79a42aa97cccbad3b63a526
- 出典データセット
- uspto-grants-1994_05
- 特許番号
- US05310737
関連ノート
読み込み中…